GLP-1 Patches: Do They Work, and What Is Actually in Them?

"GLP-1 patch" products advertise the results of an injectable drug without the injection. The reason to be skeptical is not cynicism about the sellers — it is a size limit on skin that was described in the dermatology literature a quarter of a century ago, and two molecular weights you can look up in a public database in under a minute.

Skin has a size limit, and it is about 500 daltons

The stratum corneum — the outermost layer of skin — is a barrier, and its permeability falls off sharply with molecular size. The standard statement of that bound is Bos and Meinardi's 2000 review, "The 500 Dalton rule for the skin penetration of chemical compounds and drugs"¹. The rule is not a law of physics with a hard cutoff, but it is the reason essentially every successful passive transdermal drug — nicotine, fentanyl, estradiol, scopolamine, testosterone — is a small molecule well under that mark.

Now the two numbers that decide this question. From PubChem, the public chemical database:

• •Tirzepatide: molecular weight 4,813, formula C225H348N48O68²
• •Semaglutide: molecular weight 4,114, formula C187H291N45O59³

That is roughly 9.6 times and 8.2 times the 500-dalton threshold. These are not borderline cases needing a clever formulation. They are peptides an order of magnitude too big to diffuse through intact skin.

Nothing transdermal exists to evaluate

The theory above would matter less if there were an approved product contradicting it. There is not. A live scan of every semaglutide and tirzepatide label in DailyMed — the federal drug-labeling database, nine labels for one and eight for the other — found not a single patch, transdermal, topical or film product among them⁴. Every approved product for both molecules is an injection, with the single exception of oral semaglutide tablets.

So there is no approved transdermal GLP-1, no published bioavailability figure for one, and no clinical trial of one to point at. FDA maintains a standing page on its concerns with unapproved GLP-1 drugs marketed for weight loss⁵.

What is actually in a "GLP-1 patch," then

Read the ingredient lists and these products generally fall into one of two categories, neither of which is what the name implies.

Patches containing no GLP-1 drug at all. Most commonly these carry vitamins, botanical extracts, amino acids, or compounds marketed as "GLP-1 support" or "GLP-1 activating." A patch that helps your body make more of its own GLP-1 is a fundamentally different product from one delivering semaglutide, and the marketing language often does not make the distinction easy to see. Nothing in this category is subject to the size limit above, because nothing in it is a GLP-1 receptor agonist.

Patches claiming to contain actual semaglutide or tirzepatide. These are the ones where the physics bites. There is no published evidence that a peptide of 4,000-plus daltons crosses intact stratum corneum passively in a therapeutically meaningful amount, and no bioavailability data for any such product. The molecule may genuinely be in the patch. That is not the same as it being in you.

The honest caveat

The 500 dalton rule describes passive diffusion through intact skin. It is not a claim that transdermal peptide delivery is impossible in principle, and it would be an overreach to say so. Microneedle arrays, iontophoresis and other active-delivery approaches exist specifically to bypass the barrier, and peptide delivery is an active research area. Any of that could change.

What would have to happen for it to change is specific and visible: a delivery technology, a published pharmacokinetic study showing what fraction of the dose reaches circulation, and a regulatory submission. Until those exist, a patch on a shelf is not the beneficiary of research that has not been done.

How to check one yourself

Two questions settle most of these products quickly.

Does the ingredient list name semaglutide or tirzepatide? If it does not, it is not a GLP-1 drug product regardless of what the brand name suggests, and the results in the marketing did not come from a trial of this patch.

Is there a bioavailability figure? Any product claiming to deliver a peptide through skin should be able to say what percentage arrives. If the answer is absent, the dose printed on the box describes the contents of the patch, not the exposure you receive — the same gap that makes an unstudied dose meaningless rather than merely approximate.

The same reasoning applies to the oral route, where the barrier is digestion rather than skin: our oral tirzepatide article covers why swallowing a peptide is a development program rather than a formulation choice, and why every tirzepatide label in the federal database is an injection. If injections are the objection, our oral semaglutide article covers the one approved non-injected GLP-1 and what it actually delivers. And if you would rather compare providers selling the approved injectable forms, our semaglutide provider comparison and our tirzepatide provider comparison read each one's pricing and pharmacy disclosures off its own site.

What to take from this

Semaglutide and tirzepatide weigh 4,114 and 4,813 daltons against a skin-penetration bound of roughly 500. No transdermal version of either exists among the seventeen labels the federal database holds for the two molecules. A patch claiming injectable-drug results is either not a GLP-1 drug at all, or is a GLP-1 drug with no published evidence that any of it gets past your skin — and the label will usually tell you which, if you read the ingredients rather than the brand name.